Aspire Biopharma Holdings, Inc.
ASBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 33.93 | 2.96 | 0.89 | -0.15 |
| FCF Yield | -0.07% | -0.05% | -0.05% | 0.03% |
| EV / EBITDA | 807.34 | -1,462.05 | -225.65 | -940.71 |
| Quality | ||||
| ROIC | 11.37% | 10.34% | 27.45% | -10.00% |
| Gross Margin | 45.54% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.60 | 0.58 | 0.11 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | 124,640.80% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 3.20% | 34.90% | -168.38% | 9,943.99% |
| Safety | ||||
| Net Debt / EBITDA | -0.28 | -1.12 | -0.02 | -0.15 |
| Interest Coverage | -0.77 | -1.52 | -4.91 | -1.30 |
| Efficiency | ||||
| Inventory Turnover | 0.03 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -87,313.79 | 0.00 | 0.00 | 0.00 |